Randomized, placebo-controlled trial of flax oil in pediatric bipolar disorder

Bipolar Disorders

Volumn 12, Issue 2, 2010, Pages 142-154

  Gracious, Barbara L ^a   Chirieac, Madalina C ^a   Costescu, Stefan ^a   Finucane, Teresa L ^a   Youngstrom, Eric A ^b   Hibbeln, Joseph R ^c  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

Adolescents; Bipolar disorder; Children; Flax oil; Omega 3 fatty acid

Indexed keywords

ARACHIDONIC ACID; DOCOSAPENTAENOIC ACID; FLAX OIL; ICOSAPENTAENOIC ACID; LINOLENIC ACID; OLIVE OIL; OMEGA 3 FATTY ACID; PLACEBO; UNCLASSIFIED DRUG; LINSEED OIL; UNSATURATED FATTY ACID;

ADOLESCENT; ARTICLE; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CHILDHOOD DISEASE; CLINICAL FEATURE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EYE TOXICITY; FATTY ACID BLOOD LEVEL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MOUTH DISEASE; MUSCLE DISEASE; NOSE DISEASE; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SKIN MANIFESTATION; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT DISEASE; BLOOD; DEPRESSION; METABOLISM; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TIME;

ADOLESCENT; ALPHA-LINOLENIC ACID; ARACHIDONIC ACID; BIPOLAR DISORDER; CHILD; DEPRESSION; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; FATTY ACIDS, UNSATURATED; FEMALE; HUMANS; LINSEED OIL; MALE; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 77955126446     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2010.00799.x     Document Type: Article

References (59)

1. Scheffer RE, Kowatch RA, Carmody T, Rush AJ. Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. Am J Psychiatry 2005, 162:58-64.
2. Freeman MP, Hibbeln JR, Wisner KL. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry 2006, 67:1954-1967.
3. Parker G, Gibson NA, Brotchie H, Heruc G, Rees AM, Hadzi-Pavlovic D. Omega-3 fatty acids and mood disorders. Am J Psychiatry 2006, 163:969-978.
4. McClellan J, Kowatch R, Findling RL. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2007, 46:107-125.
5. Nandagopal JJ, DelBello MP, Kowatch R. Pharmacologic treatment of pediatric bipolar disorder. Child Adolesc Psychiatr Clin N Am 2009, 18:455-469.
6. Salem N, Litman B, Kim HY, Gawrisch K. Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 2001, 36:945-959.
7. Stahl LA, Begg DP, Weisinger RS, Sinclair AJ. The role of omega-3 fatty acids in mood disorders. Curr Opin Investig Drugs 2008, 9:57-64.
8. Hibbeln JR, Nieminen LR, Blasbalg TL, Riggs JA, Lands WE. Healthy intakes of n-3 and n-6 fatty acids: estimations considering worldwide diversity. Am J Clin Nutr 2006, 83:1483S-1493S.
9. Hibbeln JR. Depression, suicide and deficiencies of omega-3 essential fatty acids in modern diets. World Rev Nutr Diet 2009, 99:17-30.
10. Noaghial S, Hibbeln JR. Cross-national comparisons of seafood consumption and rates of bipolar disorders. Am J Psychiatry 2003, 160:2222-2227.
11. Edwards R, Peet M, Shay J. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J Affect Disord 1998, 48:149-155.
12. Peet M, Murphe B, Shay J. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol Psychiatry 1998, 43:315-319.
13. Maes M, Smith RS, Christophe A. Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20:4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids. J Affect Disord 1996, 38:35-46.
14. Adams PB, Lawson S, Sanigorski A. Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids 1996, 31:S157-S161.
15. Sublette ME, Bosetti F, DeMar JC. Plasma free polyunsaturated fatty acid levels are associated with symptom severity in acute mania. Bipolar Disord 2007, 9:759-765.
16. Maes M, Christophe A, Delanghe J, Altamura C, Neels H, Meltzer HY. Lowered omega-3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res 1999, 85:275-291.
17. Mamalkis G, Kiriakakis M, Tsibinos G, Kafatos A. Depression and adipose polyunsaturated fatty acids in the survivors of the Seven Countries Study population of Crete. Prostagladins Leukot Essent Fatty Acids 2004, 70:495-501.
18. Mamalakis G, Jansen E, Cremers H, Kiriakakis M, Tsibinos G, Kafatos A. Depression and adipose and serum cholesteryl ester polyunsaturated fatty acids in the survivors of the seven countries study population of Crete. Eur J Clin Nutr 2006, 60:1016-1023.
19. Mamalakis G, Tornaritis M, Kafatos A. Depression and adipose essential polyunsaturated fatty acids. Prostaglandins Leukot Essent Fatty Acids 2002, 67:311-318.
20. McNamara RK, Jandacek R, Rider T. Deficits in docosahexaenoic acid and associated elevations in the metabolism of arachidonic acid and saturated fatty acids in the postmortem orbitofrontal cortex of patients with bipolar disorder. Psychiatry Res 2008, 160:285-299.
21. Schwarz E, Prabakaran S, Whitfield P. High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides. J Proteome Res 2008, 7:4266-4277.
22. Conklin SM, Manuck SB, Yao JK, Flory JD, Hibbeln JR, Muldoon MF. High omega-6 and low omega-3 fatty acids are associated with depressive symptoms and neuroticism. Psychosom Med 2007, 69:932-934.
23. Feart C, Peuchant E, Letenneur L. Plasma eicosapentaenoic acid is inversely associated with severity of depressive symptomatology in the elderly: data from the Bordeaux sample of the Three-City Study. Am J Clin Nutr 2008, 87:1156-1162.
24. Tiemeier H, van Tuijl HR, Hofman A, Kiliaan AJ, Breteler MM. Plasma fatty acid composition and depression are associated in the elderly: the Rotterdam Study. Am J Clin Nutr 2003, 78:40-46.
25. Clayton EH, Hanstock TL, Hirneth SJ, Kable CJ, Garg ML, Hazell PL. Long-chain omega-3 polyunsaturated fatty acids in the blood of children and adolescents with juvenile bipolar disorder. Lipids 2008, 43:1031-1038.
26. Huan M, Hamazaki K, Sun Y. Suicide attempt and n-3 fatty acid levels in red blood cells: a case-control study in China. Biol Psychiatry 2004, 56:490-496.
27. McNamara RK, Hahn CG, Jandacek R. Selective deficits in the omega-3 fatty acid docosahexaenoic acid in the postmortem orbitofrontal cortex of patients with major depressive disorder. Biol Psychiatry 2007, 62:17-24.
28. Rudin DO. The major psychoses and neuroses as omega-3 essential fatty acid deficiency syndrome: substrate pellagra. Biol Psychiatry 1981, 16:837-850.
29. Stoll AL, Severus WE, Freeman MP. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999, 56:407-412.
30. Osher Y, Bersudsky Y, Belmaker RH. Omega-3 eicosapentanoic acid in bipolar depression: report of a small open-label study. J Clin Psychiatry 2005, 66:726-739.
31. Sagduyu K, Dokucu ME, Eddy BA, Craigen G, Baldaswsano CF, Yildiz A. Omega-3 fatty acids decreased irritability of patients with bipolar disorder in an add-on, open label study. Nutr J 2005, 4:6.
32. Frangou S, Lewis M, McCrone P. Efficacy of ethyl-eicosoapentaenoic acid in bipolar depression: randomized double-blind placebo-controlled study. Br J Psychiatry 2006, 188:46-50.
33. Keck PE, Mintz J, McElroy SL. Double-blind, randomized, placebo-controlled trials of ethyl-sicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry 2006, 60:1020-1022.
34. Richardson AJ, Montgomery P. The Oxford-Durham study: a randomized controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder. Pediatrics 2005, 115:1360-1366.
35. Nemets H, Nemets B, Apter A, Bracha Z, Belmaker RH. Omega-3 treatment of childhood depression: a controlled double-blind pilot study. Am J Psychiatry 2006, 163:1098-1100.
36. Wozniak J, Biderman J, Mick E. Omega-3 fatty acid monotherapy for pediatric bipolar disorder: a prospective open-label trial. Eur Neuropsychopharmacol 2007, 17:440-447.
37. Lin P, Su K. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry 2007, 68:1056-1061.
38. Spearing MK, Robert MP, Leverich GS, Brandt D, Nolen W. Modification of the clinical global impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997, 73:159-171.
39. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978, 133:429-435.
40. Poznanski EO, Cook SC, Carroll BJ. A depression rating scale for children. Pediatrics 1979, 64:442-450.
41. Kaufman J, Birmaher B, Brent D. Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997, 36:980-988.
42. Spencer EK, Alpert M, Pouget ER. Scales for the assessment of neuroleptic response in schizophrenic children: specific measures derived from the CPRS. Psychopharmacol Bull 1994, 4:199-202.
43. Klein RG, Abikoff H, Barkley RA. Clinical trials in children and adolescents. Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines 1994, 508-509. Prien RF, Robinson DS, ., New York, NY, Raven Press
44. Moos RH, Nichol A, Moos B. Global assessment of functioning ratings and the allocation and outcome of mental health care. Psychiatr Serv 2002, 53:730-737.
45. Lagerstedt SA, Hinrichs DR, Batt SM, Magera MJ, Rinaldo P, McConnell JP. Quantitative determination of plasma c8-c26 total fatty acids for the biochemical diagnosis of nutritional and metabolic disorders. Mol Genet Metab 2001, 73:38-45.
46. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007, 39:175-191.
47. Borenstein M, Rothstein H, Cohen J, Schoenfeld D, Berlin J. Power and Precision (Version 2.1) 2001, New York, NY, Lawrence Erlbaum Assoc, Inc
48. Sackett DL, Straus SE, Richardson WS, Rosenberg W, Haynes RB. Evidence-Based Medicine: How to Practice and Teach EBM 2000, 2nd ed., New York, NY, Churchill Livingstone
49. van Belle G. Statistical Rules of Thumb 2002, New York, NY, Wiley
50. Breslow N. Covariance analysis of censored survival data. Biometrics 1974, 30:89-99.
51. Guyatt GH, Rennie D. Users' Guides to the Medical Literature 2002, Chicago, IL, AMA Press
52. Findling RL, McNamara NK, Youngstrom EA, Stansbrey R, Gracious BL, Reed MD. Double-blind 18-month trial of lithium versus divalproex maintenance treatment in pediatric bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005, 44:409-417.
53. Raudenbush SW, Bryk AS. Hierarchical Linear Models: Applications and Data Analysis Methods 2002, 2nd ed., Newbury Park, CA, Sage Publications, Inc.
54. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979, 6:65-70.
55. Campbell DT, Kenny DA. A Primer on Regression Artifacts 1999, New York, NY, The Guilford Press
56. Gerster H. Can adults adequately convert alpha-linolenic acid (18:3n-3) to eicosapentaenoic acid (20:5n-3) and docosahexaenoic acid (22:6n-3)? Intern J Vit Nutr Res 1998, 68:159-173.
57. Schaeffer L, Gohlke H, Muller M. Common genetic variants of the FDAS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids. Hum Mol Genet 2006, 15:1745-1756.
58. Bierenbaum ML, Reichstein R, Watkins TR. Reducing atherogenic risk in hyperlipemic humans with flax seed supplementation: a preliminary report. J Am Coll Nutr 1993, 12:501-504.
59. Nestel PJ, Pomeroy SE, Sasahara T. Arterial compliance in obese subjects is improved with dietary plan n-3 fatty acid from flaxseed oil despite increased LDL oxidizability. Arterioscler Thromb Vasc Biol 1996, 17:1163-1170.